Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BILR 355 BS Monotherapy and Combination Therapy in HIV-1
NCT00294372Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BILR 355 in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Started Feb 2006; status: terminated.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00294372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294372.